49,138 Certara, Inc. $CERT Shares Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP grew its holdings in Certara, Inc. (NASDAQ:CERT – Free Report) by 341.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 63,508 shares of the company’s stock after acquiring an additional 49,138 shares during the period. Fulcrum Asset Management LLP’s holdings in Certara were worth $588,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in CERT. Integrated Wealth Concepts LLC purchased a new stake in Certara during the 2nd quarter worth $39,000. GAMMA Investing LLC increased its holdings in Certara by 21.2% in the 3rd quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock valued at $90,000 after purchasing an additional 1,710 shares in the last quarter. NorthRock Partners LLC acquired a new stake in Certara in the 2nd quarter valued at $68,000. State of Wyoming purchased a new position in Certara in the second quarter valued at about $72,000. Finally, Perigon Wealth Management LLC purchased a new position in Certara in the second quarter valued at about $80,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Price Performance

Shares of CERT stock opened at $11.57 on Monday. The firm has a fifty day moving average of $9.70 and a two-hundred day moving average of $7.40. The firm has a market cap of $1.76 billion, a P/E ratio of -27.55 and a beta of 1.30. Certara, Inc. has a 1-year low of $4.45 and a 1-year high of $12.61. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.58 and a quick ratio of 2.58.

Certara (NASDAQ:CERT – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. The business had revenue of $94.90 million during the quarter, compared to the consensus estimate of $92.01 million. Certara had a positive return on equity of 3.36% and a negative net margin of 16.14%. The company’s revenue for the quarter was down 9.3% compared to the same quarter last year. During the same period last year, the firm earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. As a group, research analysts anticipate that Certara, Inc. will post 0.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CERT has been the topic of a number of recent research reports. UBS Group restated a “neutral” rating and set a $13.00 price objective on shares of Certara in a research note on Friday, November 6th. Weiss Ratings upgraded Certara from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, November 9th. KeyCorp increased their target price on Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Jefferies Financial Group reiterated a “hold” rating and set a $12.00 target price on shares of Certara in a report on Friday, November 6th. Finally, Barclays boosted their price target on Certara from $9.00 to $12.00 and gave the stock an “equal weight” rating in a research report on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.92.

Get Our Latest Stock Analysis on Certara

About Certara

(Free Report)

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.

Further Reading

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).

Institutional Ownership by Quarter for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.